市场调查报告书
商品编码
1411269
植入式心臟復律去颤器市场- 按产品(经静脉ICD、皮下ICD)、按类型(单腔、双腔、双心室设备)、最终用途(医院、门诊手术中心)和预测,2024- 2032 年Implantable Cardioverter Defibrillators Market - By Product (Transvenous ICDs, Subcutaneous ICDs), By Type (Single-Chamber, Dual-Chamber, Biventricular Devices), End-use (Hospitals, Ambulatory Surgical Centers) & Forecast, 2024-2032 |
预计从2024 年到2032 年,植入式心律转復除颤器市场规模将增加6.4% 以上。心血管疾病,特别是心律不整和心臟骤停的盛行率不断增加,正在推动对植入式心律转復除颤器(ICD) 的需求。人口老化和生活方式相关风险因素的增加正在导致 ICD 技术不断进步。例如,2023 年 12 月,PROFID EHRA 研究启动,这是第一个重新评估在患有心臟衰竭的心臟病倖存者中植入除颤器的标准做法的临床试验。
人们对预防性医疗措施的认识不断提高,加上有利的报销政策的涌入,将刺激植入式心臟復律去颤器的采用。正在进行的研发活动,包括远端监控和无引线设备的集成,正在进一步提高产品的有效性和可访问性。此外,医疗保健提供者和设备製造商之间的策略合作以及对创新心臟解决方案不断增加的监管支持将补充产业的扩张。
植入式心律转復除颤器市场按产品、类型、最终用途和地区划分。
根据产品类型,预计 2024 年至 2032 年皮下 ICD 领域的行业份额将以 6.9% 的复合CAGR增长。这一增长可归因于皮下植入式心律转復除颤器(S-ICD) 因其微创性而受到越来越多的青睐。自然。感染风险的降低、患者舒适度的提高以及 S-ICD 技术的不断进步将推动该产品在危及生命的心律不整治疗中的采用。
由于对复杂心律不整管理的需求不断增加,双腔 ICD 类型细分市场的植入式心律转復除颤器产业规模预计在 2024 年至 2032 年间将以 7% 的CAGR扩大。双室 ICD 增强的感测能力、提高的检测精度和优化的治疗交付也将有助于满足患有各种心臟病的患者的复杂需求。
从地区来看,2024 年至 2032 年间,欧洲植入式心律转復除颤器产业规模的CAGR将达到6.1%。这一增长可归因于人口老化、心血管疾病发生率的增加以及心臟设备的更高技术进步。此外,支持性医疗保健政策的出台、预防心臟病学意识的提高以及医疗保健组织和设备製造商之间的策略合作将推动该地区的行业扩张。
Implantable cardioverter defibrillators market size is projected to expand at over 6.4% from 2024 to 2032. The increasing prevalence of cardiovascular diseases, especially arrhythmias and sudden cardiac arrests is fueling the demand for implantable cardioverter defibrillators (ICDs). The aging population and growing lifestyle-related risk factors is leading to rising advancements in ICD technology. For instance, in December 2023, the PROFID EHRA study was launched, representing the first clinical trial for reevaluating the standard practice of implanting defibrillators in heart attack survivors with heart failure.
The rising awareness about preventive healthcare measures coupled with the influx of favorable reimbursement policies will stimulate the adoption of implantable cardioverter defibrillators. The ongoing R&D activities, including the integration of remote monitoring and leadless devices is further enhancing the product effectiveness and accessibility. Additionally, strategic collaborations between healthcare providers and device manufacturers along with the increasing regulatory support for innovative cardiac solutions will complement the industry expansion.
The implantable cardioverter defibrillators market is segregated into product, type, end-use, and region.
Based on product type, the industry share from the subcutaneous ICDs segment is projected to rise at 6.9% CAGR from 2024 to 2032. The growth can be ascribed to the increasing preference for subcutaneous implantable cardioverter defibrillators (S-ICDs) due to their minimally invasive nature. The reduced infection risk, improved patient comfort, and increasing advancements in S-ICD technology will drive the product adoption in the management of life-threatening cardiac arrhythmias.
Implantable cardioverter defibrillators industry size from the dual-chamber ICDs type segment is estimated to expand at 7% CAGR between 2024 and 2032, owing to the increasing demand for sophisticated arrhythmia management. The enhanced sensing capabilities, improved detection accuracy, and optimized therapy delivery of dual chamber ICDs will also help address the complex needs of patients with various cardiac conditions.
Regionally, the Europe implantable cardioverter defibrillators industry size will depict 6.1% CAGR between 2024 and 2032. The growth can be attributed to the aging population, increasing incidence of cardiovascular diseases, and the higher technological advancements in cardiac devices. Moreover, the introduction of supportive healthcare policies, the rising awareness of preventive cardiology, and strategic collaborations between healthcare organizations and device manufacturers will drive the industry expansion across the region.